Annals of Internal Medicine Po E Ao hddresses:Dr,Sshulr,gami e Inemadonab ment:Isabelle Boutron,Universite Paris 7 Denis Diderot Assistance Publique des Hopitaux de Paris,INSERM:P.J.Deve School of Hygiene&Tropical Mcdicne:Susan Ell re.Uni 8H aOadcaeweR6i2.oobk sity of Author Contributions:Conception:K.F.D.G. of Clinical Oncology;Brian Haynes,MeMaster University;Sall I M y or of the da a:K.F.Schulz.D.Mohe ford:Astrid a Philippa,University of Adelaide:Don Minckler,Uni- tent K.F n,D David Moher.O Method aiicD.man D.Moher Lof th row e:Drum th E APPENDIX:THE CONSORT GROUP CONTRIBUTORS To CONSORT 2010 who did not Mike Clarke,UK Coc 1 June 201Anl of nmal Medicine Volume 152Number 1w-23 第31页
Current Author Addresses: Dr. Schulz: Family Health International, PO Box 13950, Research Triangle Park, NC 27709. Dr. Altman: Centre for Statistics in Medicine, University of Oxford, Wolfson College Annexe, Linton Road, Oxford OX2 6UD, United Kingdom. Dr. Moher: Ottawa Methods Centre, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Department of Epidemiology and Community Medicine, University of Ottawa, 501 Smyth Road, 6th Floor, Critical Care Wing, Room W6112, Ottawa, Ontario K1H 8L6, Canada. Author Contributions: Conception and design: K.F. Schulz, D.G. Altman, D. Moher. Analysis and interpretation of the data: K.F. Schulz, D. Moher. Drafting of the article: K.F. Schulz, D.G. Altman, D. Moher. Critical revision of the article for important intellectual content: K.F. Schulz, D.G. Altman, D. Moher. Final approval of the article: K.F. Schulz, D.G. Altman, D. Moher. Statistical expertise: D.G. Altman, K.F. Schulz. Obtaining of funding: D. Moher. Administrative, technical, or logistic support: D. Moher. Collection and assembly of data: K.F. Schulz, D. Moher. APPENDIX: THE CONSORT GROUP CONTRIBUTORS TO CONSORT 2010 Douglas G. Altman, Centre for Statistics in Medicine, University of Oxford; Virginia Barbour, PLoS Medicine; Jesse A. Berlin, Johnson & Johnson Pharmaceutical Research and Development; Isabelle Boutron, Universite´ Paris 7 Denis Diderot, Assistance Publique des Hoˆpitaux de Paris, INSERM; P.J. Devereaux, McMaster University; Kay Dickersin, Johns Hopkins Bloomberg School of Public Health; Diana Elbourne, London School of Hygiene & Tropical Medicine; Susan Ellenberg, University of Pennsylvania School of Medicine; Val Gebski, University of Sydney; Steven Goodman, Clinical Trials: Journal of the Society for Clinical Trials; Peter C. Gøtzsche, Nordic Cochrane Centre; Trish Groves, BMJ; Steven Grunberg, American Society of Clinical Oncology; Brian Haynes, McMaster University; Sally Hopewell, Centre for Statistics in Medicine, University of Oxford; Astrid James, The Lancet; Peter Juhn, Johnson & Johnson; Philippa Middleton, University of Adelaide; Don Minckler, University of California, Irvine; David Moher, Ottawa Methods Centre, Clinical Epidemiology Program, Ottawa Hospital Research Institute; Victor M. Montori, Knowledge and Encounter Research Unit, Mayo Clinic College of Medicine; Cynthia Mulrow, Annals of Internal Medicine; Stuart Pocock, London School of Hygiene & Tropical Medicine; Drummond Rennie, JAMA; David L. Schriger, Annals of Emergency Medicine; Kenneth F. Schulz, Family Health International; Iveta Simera, EQUATOR Network; and Elizabeth Wager, Sideview. Contributors to CONSORT 2010 who did not attend the Montebello meeting: Mike Clarke, UK Cochrane Centre, and Gordon Guyatt, McMaster University. Annals of Internal Medicine www.annals.org 1 June 2010 Annals of Internal Medicine Volume 152 • Number 11 W-293 第 31 页
Doxorub icin,and Mitom Castric Cancer Treatment in Operable By R.C.Coombes,P.S.Schein,C.E.D.Chilvers WiksBeret,MsA.Rumten.D.Amadori. esA.Villar-Grimalt,C.McArdle,H.F.Rou hundred pa c 021 mito 1984 041 of this fin 281 ed by the m ly,and ts,the id ding.We c nt che cia (57%) ng na 6)andn py cer,but th furthe A 8.1362- Amorican Soci- gland and Wales. Many patients have wide tive he rge's tiga er ch.Su o San trointe nal cancers in their rela e resistanc Adriamyein (:Adria Columt s.OH).and mitomycin (F patients withadvance gastriccancer,and this en.The Ne MrdicalOacol the E (E( gastric can nce patients nbes MD.O studies regimens had already b of this study,but none had r Dortcdathe 1362 Joumal of Clinical Oncology,Vol 8.No 8 (August),19901 pp 1362-1365 第32页
Copyright © 1990 by the American Society of Clinical Oncology. All rights reserved. Information downloaded from www.jco.org and provided by NIH LIBRARY on January 22, 2007 from 128.231.88.4. 义 第 32 页
FAM v NO TREATMENT IN GASTRIC CANCER 1363 al.We FAM Table Patient Entry by of patients with operable gastriccancer. ital,Milan.Ital PATIENTS AND METHODS % Patients 70, 9 nrothe Thi 4121 11 King eui m.The Net e)d sit ht ha s were ma ema eat of s ged leu a(WBC2.5】 a (pla ad p (sc e of the Pathology cal pr to at eac le thi ver Data Collection ed in a bo chemotherany Oiendhcoe ned in the natie requested at entry to the 密名签惠是灯名aa4 第33页
Copyright © 1990 by the American Society of Clinical Oncology. All rights reserved. Information downloaded from www.jco.org and provided by NIH LIBRARY on January 22, 2007 from 128.231.88.4. 义 第 33 页
1364 COOMBES ET AL Statistical Methods and Mei d the ank rms of the tr 图 g patients'ch RESULTS 1001 men.40 women:mean 6.6 years patients (98 men,50 women:mean age.56. 编 1第 f pa L ZZZ N ccurred 78%of patients.nor n 0 4kg in weight loss on 的 were simila with spect to single o e(N)de llP.. mined pathologically.Well-differentiated and tiated esent i ures Used by Treatment Arm inTable3. up of 68 m nths 56 (7 of 13)of patintsin ce in d survival is not ted and un with a media ot recorded 第34页
Copyright © 1990 by the American Society of Clinical Oncology. All rights reserved. Information downloaded from www.jco.org and provided by NIH LIBRARY on January 22, 2007 from 128.231.88.4. 义 第 34 页
FAM NO TREATMENT IN GASTRIC CANCER 1365 100 60 vidence of a diffe ential treatmen 70 the 125 patients with the most advanc ced dises that is,with and positiveno 9nk0-1151p-02 45 isat c e died I arm One forty-six patien have 61 Fou Fig.ven-rvivolin gtric cn ure,thes .On A number of subsets were defined ret tively and the with FAMo treatment in stage Il and stage Il patients sho slight evide ardial infars and a cardiom pathy car e to nths wed similar effects with rank test his death was treatment-re ated The other pa- 0.001,df 1.P=.97;node-positive:log-rank test, hat y day o 100 80- 860- ath in Sixty-seve 20 o-154-1p-02 nine rec Years ce rand fusal (11).toxicity with or withou det istra Fig2.veroll ureling 第35页
Copyright © 1990 by the American Society of Clinical Oncology. All rights reserved. Information downloaded from www.jco.org and provided by NIH LIBRARY on January 22, 2007 from 128.231.88.4. 义 第 35 页